Background

Alveolar fibrin deposition is a hallmark of acute lung injury, resulting from activation of coagulation and inhibition of fibrinolysis. Previous studies have shown that mechanical ventilation with high tidal volumes may aggravate lung injury in patients with sepsis and acute lung injury. The authors sought to determine the effects of mechanical ventilation on the alveolar hemostatic balance in patients without preexistent lung injury.

Methods

Patients scheduled for an elective surgical procedure (lasting > or = 5 h) were randomly assigned to mechanical ventilation with either higher tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure (PEEP) or lower tidal volumes of 6 ml/kg and 10 cm H2O PEEP. After induction of anesthesia and 5 h later bronchoalveolar lavage fluid and blood samples were obtained, and markers of coagulation and fibrinolysis were measured.

Results

In contrast to mechanical ventilation with lower tidal volumes and PEEP (n = 21), the use of higher tidal volumes without PEEP (n = 19) caused activation of bronchoalveolar coagulation, as reflected by a marked increase in thrombin-antithrombin complexes, soluble tissue factor, and factor VIIa after 5 h of mechanical ventilation. Mechanical ventilation with higher tidal volumes without PEEP caused an increase in soluble thrombomodulin in lavage fluids and lower levels of bronchoalveolar activated protein C in comparison with lower tidal volumes and PEEP. Bronchoalveolar fibrinolytic activity did not change by either ventilation strategy.

Conclusions

Mechanical ventilation with higher tidal volumes and no PEEP promotes procoagulant changes, which are largely prevented by the use of lower tidal volumes and PEEP.

PULMONARY inflammation is characterized by local generation of proinflammatory mediators and a procoagulant shift of the alveolar hemostatic balance, promoting fibrin depositions within the airways.1,2Disturbances in alveolar fibrin turnover have been demonstrated in patients with pneumonia3–6and acute respiratory distress syndrome (ARDS).3,7Whereas fibrin formation may aid in host protection, such as the containment of infectious agents during pulmonary infection and in maintaining or repairing the endothelial-epithelial barrier, on the other hand, coagulation products such as thrombin and fibrin have significant proinflammatory properties, potentially compromising pulmonary integrity and function.1,2In its most extreme form, bronchoalveolar fibrin formation may compromise pulmonary function, as may occur with severe ARDS.

In severe lung injury, ventilatory support is almost invariably mandatory, but it is increasingly recognized that mechanical ventilation itself may aggravate or even initiate lung injurious processes.8,9The so-called ventilator-associated lung injury is characterized by several pathophysiologic sequelae, including local generation of inflammatory mediators, constituting a pulmonary environment that is highly proinflammatory. Another hallmark of ventilator-associated lung injury in patients with severe lung injury is the activation of bronchoalveolar coagulation.5,6In patients with ARDS, mechanical ventilation with lower tidal volumes improves patient survival,10most likely by limiting generation of proinflammatory mediators, both locally in the lungs and systemically.11It is unknown whether (mechanical ventilation–induced) alterations in the alveolar hemostatic balance contribute to outcome in mechanically ventilated patients. Moreover, there is ongoing debate on whether patients without  preexistent lung injury would benefit from mechanical ventilation with lower tidal volumes, because large clinical trials have only investigated patients with acute lung injury and ARDS in the intensive care unit. Recently, the pulmonary and systemic inflammatory effects of mechanical ventilation were investigated in patients during major surgery, showing little alteration in the inflammatory responses.12,13 

The aim of the current study was to characterize the effects of mechanical ventilation on the alveolar hemostatic balance. A randomized controlled trial was performed comparing two mechanical ventilation strategies in patients without preexistent lung injury who were scheduled to undergo a major surgical procedure.

Patients

The study protocol was approved by the Medical Ethics Committee of the University of Amsterdam (Amsterdam, The Netherlands), and informed consent was obtained from all patients. Adult patients were eligible if they were scheduled to undergo a surgical procedure of 5 h or more, and all involved physicians (surgeon, anesthesiologist, pulmonologist) consented with the study procedures, assuring safety of the patient. Exclusion criteria included a history of any lung disease, use of immunosuppressive medication, recent infections, previous thromboembolic disease, recent admission to the intensive care unit for ventilatory support, and participation in another clinical trial.

Study Protocol

All patients received routine anesthesia according to protocol, including intravenous propofol (2–3 mg/kg, thereafter 6–12 mg · kg−1· h−1), fentanyl (2–3 μg/kg, thereafter as required), and rocuronium (as required); and epidural bupivacaine (0.125%)–fentanyl (2.5 μg/ml). The ventilatory protocol consisted of volume-controlled mechanical ventilation at an inspired oxygen fraction of 0.40, inspiratory to expiratory ratio of 1:2, and a respiratory rate adjusted to normocapnia. Randomization was performed by drawing a presealed envelope; patients were randomly assigned to mechanical ventilation with either tidal volumes of 12 ml/kg (ideal body weight, calculated according to the formula as described before)10and no positive end-expiratory pressure (PEEP) or 6 ml/kg and 10 cm H2O PEEP. Anesthesiologists were allowed to change the ventilation protocol at any time point upon the surgeon's request, or if there was any concern about patient's safety. If the surgical procedure exceeded 5 h, anesthesiologists were allowed to change the ventilation strategy after the second sampling (blood and bronchoalveolar lavage). Patients were followed up until hospital discharge or death.

Bronchoscopy and bronchoalveolar lavage were performed twice on all patients: the first just after initiation of mechanical ventilation in either the right middle lobe or lingula, and the second performed in the contralateral lung 5 h thereafter, either perioperatively or directly postoperatively. Lavage fluid was obtained as previously described.4,6,14In short, bronchoalveolar lavage was performed by an experienced pulmonologist in a standardized fashion according to the guidelines of the American Thoracic Society, using a flexible fiberoptic video-bronchoscope. Seven successive 20-ml aliquots of prewarmed normal saline were instilled and aspirated immediately with low suction (general recovery 10–15 ml). For coagulation assays, sodium citrate and benzamidin were added to the lavage fluids to a final concentration of 10 and 20 mm, respectively. Citrated (0.109 m) blood samples were drawn before both lavages, and hourly blood gas analyses were performed. Cell-free supernatants were stored at −80°C until analysis.

Assays for Coagulation and Fibrinolysis

Thrombin–antithrombin complex (TATc), soluble tissue factor, factor VIIa, tissue-type plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), plasminogen activator activity, soluble thrombomodulin, and activated protein C (APC) concentrations were measured as described before.15–17 

Statistical Analysis

The required sample size was calculated from data from our previous investigations on pulmonary hemostasis.5,6To detect differences in bronchoalveolar TATc concentrations in the study groups at a two-sided significance level of 5% with a power of 80%, the number of patients to be studied in each group was at least 19.

Baseline characteristics of the randomized patient groups were compared with the Student t  test or Mann–Whitney U test, where appropriate. For categorical data, the chi-square test was used. Differences within groups were analyzed with a Wilcoxon signed-rank test for paired samples comparing t = 5 versus  t = 0 h, and the Mann–Whitney U test was used to compare the changes over time between the two randomization groups. All results are expressed as mean ± SD. A P  value of less than 0.05 was considered statistically significant. All statistical analyses were performed with SPSS 12.0 (SPSS, Chicago, IL).

Patients

Seventy-four consecutive patients who were scheduled to undergo an elective surgical procedure of 5 h or more were screened in the period December 2003 through March 2005 (fig. 1). Twenty-eight patients were excluded, leaving 46 patients for randomization. Five patients were randomized but excluded from final analysis, because the initial surgical procedure was converted by the surgeon into another shorter operation (< 3 h), and only one bronchoalveolar lavage was performed. One patient was randomized, but no lavages were performed upon the surgeon's request after induction of anesthesia. In total, 40 patients completed the study protocol. There were no major differences between the two randomization groups with regard to baseline characteristics (table 1).

Fig. 1. CONSORT diagram. BAL = bronchoalveolar lavage; HVT/ZEEP = tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure; LVT/PEEP = tidal volumes of 6 ml/kg ideal body weight and 10 cm H2O positive end-expiratory pressure; MV = mechanical ventilation. 

Fig. 1. CONSORT diagram. BAL = bronchoalveolar lavage; HVT/ZEEP = tidal volumes of 12 ml/kg ideal body weight and no positive end-expiratory pressure; LVT/PEEP = tidal volumes of 6 ml/kg ideal body weight and 10 cm H2O positive end-expiratory pressure; MV = mechanical ventilation. 

Table 1. Baseline Characteristics of Patients 

Table 1. Baseline Characteristics of Patients 
Table 1. Baseline Characteristics of Patients 

There were no adverse events related to the bronchoalveolar lavages. One surgeon reported hepatic congestion and requested PEEP levels to be reduced (patient ventilated with lower tidal volumes and PEEP). Aside from the mechanical ventilator settings (tidal volume, PEEP, and respiratory rate), there were no significant differences in perioperative hemodynamic parameters (table 2and fig. 2). In particular, peak pressures were not different between the study groups during 5 h of mechanical ventilation.

Table 2. Perioperative Parameters 

Table 2. Perioperative Parameters 
Table 2. Perioperative Parameters 

Fig. 2. Perioperative parameters. Tidal volumes (VT), respiratory rate (respir. rate), and maximal pressures (Pmax) in patients ventilated with lower tidal volumes and positive end-expiratory pressure (  open symbols , n = 21) and patients ventilated with higher tidal volumes and no positive end-expiratory pressure (  closed symbols , n = 19). There are no significant differences in arterial blood gas analyses at any time point. Data are mean ± SD. Note 1 kPa = 7.5 mmHg. MV = mechanical ventilation; Paco2= partial pressure of alveolar carbon dioxide; Pao2= partial pressure of alveolar oxygen. 

Fig. 2. Perioperative parameters. Tidal volumes (VT), respiratory rate (respir. rate), and maximal pressures (Pmax) in patients ventilated with lower tidal volumes and positive end-expiratory pressure (  open symbols , n = 21) and patients ventilated with higher tidal volumes and no positive end-expiratory pressure (  closed symbols , n = 19). There are no significant differences in arterial blood gas analyses at any time point. Data are mean ± SD. Note 1 kPa = 7.5 mmHg. MV = mechanical ventilation; Paco2= partial pressure of alveolar carbon dioxide; Pao2= partial pressure of alveolar oxygen. 

Bronchoalveolar Coagulation and Fibrinolysis

Mechanical ventilation with higher tidal volumes and zero PEEP (HVT/ZEEP) caused activation of bronchoalveolar coagulation, as reflected in a marked increase in TATc, soluble tissue factor, and factor VIIa after 5 h of mechanical ventilation (all P < 0.001 vs.  t = 0; fig. 3). In patients ventilated with lower tidal volumes and 10 cm H2O PEEP (LVT/PEEP), only soluble tissue factor was slightly increased (P < 0.01 vs.  t = 0; fig. 3B) and far less pronounced than in patients with HVT/ZEEP (P < 0.001 between groups; fig. 3B).

Fig. 3. Thrombin–antithrombin complexes (TATc , A ), soluble tissue factor (sTF , B ), and factor VIIa (FVIIa , C ) in bronchoalveolar lavage fluid recovered at baseline (t = 0) and after 5 h (t = 5) from patients mechanically ventilated with 6 ml/kg and 10 cm H2O positive end-expiratory pressure (LVT/PEEP, n = 21) or with 12 ml/kg and zero positive end-expiratory pressure (HVT/ZEEP, n = 19). * Difference from t = 0 in HVT/ZEEP (  P < 0.001). † Difference from t = 0 in LVT/PEEP (  P < 0.01). ‡ Intergroup difference (  P < 0.001). Data are mean ± SD. 

Fig. 3. Thrombin–antithrombin complexes (TATc , A ), soluble tissue factor (sTF , B ), and factor VIIa (FVIIa , C ) in bronchoalveolar lavage fluid recovered at baseline (t = 0) and after 5 h (t = 5) from patients mechanically ventilated with 6 ml/kg and 10 cm H2O positive end-expiratory pressure (LVT/PEEP, n = 21) or with 12 ml/kg and zero positive end-expiratory pressure (HVT/ZEEP, n = 19). * Difference from t = 0 in HVT/ZEEP (  P < 0.001). † Difference from t = 0 in LVT/PEEP (  P < 0.01). ‡ Intergroup difference (  P < 0.001). Data are mean ± SD. 

Neither mechanical ventilation strategies were associated with changes in bronchoalveolar plasminogen activator activity (both within groups and between groups), despite a slight up-regulation of PAI-1 with HVT/ZEEP (P < 0.05 vs.  t = 0; fig. 4). tPA was increased in both groups (both P < 0.001 vs.  t = 0; fig. 4C), slightly more in HVT/ZEEP ventilation (P < 0.05 between groups).

Fig. 4. Plasminogen activator activity (PAA , A ), plasminogen activator inhibitor type 1 (PAI-1 , B ), and tissue-type plasminogen activator (tPA , C ) in bronchoalveolar lavage fluid recovered at baseline (t = 0) and after 5 h (t = 5) from patients mechanically ventilated with 6 ml/kg and 10 cm H2O positive end-expiratory pressure (LVT/PEEP, n = 21) or with 12 ml/kg and zero positive end-expiratory pressure (HVT/ZEEP, n = 19). * Difference from t = 0 in HVT/ZEEP (  P < 0.05). † Difference from t = 0 in LVT/PEEP (  P < 0.001). ‡ Difference from t = 0 in HVT/ZEEP (  P < 0.001). § Intergroup difference (  P < 0.05). Data are mean ± SD. 

Fig. 4. Plasminogen activator activity (PAA , A ), plasminogen activator inhibitor type 1 (PAI-1 , B ), and tissue-type plasminogen activator (tPA , C ) in bronchoalveolar lavage fluid recovered at baseline (t = 0) and after 5 h (t = 5) from patients mechanically ventilated with 6 ml/kg and 10 cm H2O positive end-expiratory pressure (LVT/PEEP, n = 21) or with 12 ml/kg and zero positive end-expiratory pressure (HVT/ZEEP, n = 19). * Difference from t = 0 in HVT/ZEEP (  P < 0.05). † Difference from t = 0 in LVT/PEEP (  P < 0.001). ‡ Difference from t = 0 in HVT/ZEEP (  P < 0.001). § Intergroup difference (  P < 0.05). Data are mean ± SD. 

There was a trend toward lower levels of bronchoalveolar APC with HVT/ZEEP as opposed to a trend toward higher APC with LVT/PEEP (fig. 5A). Between-group analysis did show a difference in changes of APC levels over time (P < 0.05 between groups). Mechanical ventilation with HVT/ZEEP caused an increase in soluble thrombomodulin as measured in lavage fluids (P < 0.05 vs.  t = 0; fig. 5B), which was not with LVT/PEEP.

Fig. 5. Activated protein C (APC , A ) and soluble thrombomodulin (sTM , B ) in bronchoalveolar lavage fluid recovered at baseline (t = 0) and after 5 h (t = 5) from patients mechanically ventilated with 6 ml/kg and 10 cm H2O positive end-expiratory pressure (LVT/PEEP, n = 21) or with 12 ml/kg and zero positive end-expiratory pressure (HVT/ZEEP, n = 19). * Difference from t = 0 in HVT/ZEEP (  P < 0.05). † Intergroup difference (  P < 0.05). Data are mean ± SD. 

Fig. 5. Activated protein C (APC , A ) and soluble thrombomodulin (sTM , B ) in bronchoalveolar lavage fluid recovered at baseline (t = 0) and after 5 h (t = 5) from patients mechanically ventilated with 6 ml/kg and 10 cm H2O positive end-expiratory pressure (LVT/PEEP, n = 21) or with 12 ml/kg and zero positive end-expiratory pressure (HVT/ZEEP, n = 19). * Difference from t = 0 in HVT/ZEEP (  P < 0.05). † Intergroup difference (  P < 0.05). Data are mean ± SD. 

Systemic Hemostasis

During surgery, both systemic procoagulant and fibrinolytic activity were increased. In patients ventilated with HVT/ZEEP, there was an increase in TATc (6.1 ± 0.76 vs.  5.78 ± 1.10 ng/ml; P < 0.05) and plasminogen activator activity (103 ± 5.9 vs.  99 ± 6.5%; P < 0.01); in patients ventilated with LVT/PEEP, there was also an increase in TATc (5.63 ± 1.13 vs.  4.86 ± 1.09 ng/ml; P < 0.01), but only a trend toward higher plasminogen activator activity (102 ± 8.7 vs.  99 ± 6.6%). The changes over time were not different between the two mechanical ventilation strategies.

Postoperative Course

In the postoperative recovery, 28 patients had follow-up chest radiographs. There were no differences in postoperative arterial blood gas analyses (HVT/ZEEP vs.  LVT/PEEP): partial pressure of oxygen 117 ± 42 versus  123 ± 53 mmHg, partial pressure of carbon dioxide 43 ± 5 versus  42 ± 5 mmHg, and pH 7.36 ± 0.053 versus  7.34 ± 0.051. There were no differences in incidence of pulmonary complications (e.g. , acute lung injury, pneumonia) between the two study groups; in each study group, there was one patient requiring prolonged mechanical ventilation for respiratory failure after surgery. One patient ventilated with LVT/PEEP died postoperatively of multiple organ failure after complicated hemihepatectomy. All other patients were discharged home.

Although mechanical ventilation with lower tidal volumes is generally considered to be protective in patients with acute lung injury, there is ongoing debate on the ideal tidal volumes in patients without preexistent lung injury. We here demonstrated that mechanical ventilation has significant effects on bronchoalveolar hemostasis: Although the duration of mechanical ventilation was only 5 h and no differences were observed in clinical parameters during the surgical procedure or in the recovery phase, local procoagulant activity was increased in the group of patients with noninjured lungs ventilated with 12 ml/kg and without the use of PEEP. Furthermore, we showed that mechanical ventilation with lower tidal volumes and PEEP can largely prevent these procoagulant changes. Simultaneously, there is up-regulation of plasminogen activation, which is not immediately reflected in increased fibrinolytic activity, perhaps—at least in patients ventilated with HVT/ZEEP—because of inhibitory effects of PAI-1. Finally, we demonstrated that mechanical ventilation with HVT/ZEEP causes generation of more soluble fragments of thrombomodulin in the bronchoalveolar spaces, potentially leading to an impaired activation of the protein C system. In summary, mechanical ventilation with HVT/ZEEP seems to promote fibrin depositions within the airways by three mechanisms: increased procoagulant activity via  the extrinsic pathway, a relative insufficiency of the anticoagulant protein C system, and inhibition of fibrinolysis by PAI-1.

A “multiple-hit” model of lung injury can be theorized whereby predisposing conditions, such as injurious mechanical ventilation during surgery, may result in pulmonary inflammation (the “primary hit”). Then, several “second hits,” such as transfusion of blood products,18prolonged (injurious) mechanical ventilation,11,19aspiration,10,20shock or sepsis,10,20and ventilator-associated pneumonia,21may all cause additional lung injury, finally resulting in full-blown ARDS with high morbidity and mortality. Although the current study was not designed to investigate clinical outcome, no differences were observed in the postoperative course between the study groups. However, the alterations in bronchoalveolar hemostasis may indicate that mechanical ventilation potentially has harmful effects, even in patients without acute lung injury.

The currently described changes in pulmonary hemostasis are similar as those previously described in patients with pneumonia or ARDS3–6and in human volunteers with endotoxin-induced pulmonary inflammation.15,22Consistently, increased procoagulant activity is reported, mostly related to the extrinsic coagulation pathway. It is likely that this activation is mediated by tissue factor expression on epithelial cells and mononuclear cells in the bronchoalveolar compartment. In the case of activation of epithelial and endothelial cells, by pathogens, excessive inflammation, or—as probably is the case during mechanical ventilation—mechanical strain, there will be disruption of the endothelial–epithelial barrier. Transudation of plasma into the bronchoalveolar compartment will subsequently initiate coagulation within the airways. We speculate that this is the mechanism leading to immediate “sealing” of the damaged area, providing injury containment, and initiating other repair systems. Also, PAI-1 up-regulation has been found consistently in patients with pneumonia,3–6in patients with ARDS,3,7and in our patients ventilated with HVT/ZEEP. Although in the current clinical settings this did not lead to a suppression of fibrinolytic activity, prolonged mechanical ventilation could lead to even higher levels of PAI-1 and more interference with fibrinolytic activity, as we demonstrated in patients developing ventilator-associated pneumonia.5,6tPA antigens levels were increased by ventilation with both low and high tidal volumes. This is in contrast to in vitro  studies by Dr. Günther's group, in which various cell lines all showed a down-regulation of tPA messenger RNA expression upon inflammatory stimuli.23However, the same group reported in an in vivo  model of endotoxin-induced lung injury that tPA is indeed up-regulated in both structural (alveolar type II cells, endothelial cells) and host defense cells (alveolar macrophages) in mouse lungs.24Also in our recent report on endotoxin-induced lung inflammation in human volunteers, increased levels of tPA were observed.15It is thought that this early activation of the fibrinolytic system is involved in tissue remodeling.25 

We have shown before that in patients with pneumonia, protein C activation is suppressed, as well as after instillation of endotoxin in lungs of healthy volunteers.15,26Mechanical ventilation with HVT/ZEEP induced shedding of soluble thrombomodulin into the airspaces, which is generally believed to represent epithelial or endothelial damage. On the other hand, there was a trend toward lower levels of APC, which was clearly opposite of the effect seen with LVT/PEEP ventilation. Recombinant human APC (rhAPC) has been shown to reduce mortality in patients with severe sepsis,27in whom protective effects are believed to be beyond its anticoagulant properties. Despite vast data from in vitro  and animal studies, however, it is still unclear how rhAPC acts in vivo . Systemic administration of rhAPC has significant effects in the lungs,15,28suggesting that pulmonary effects of rhAPC may contribute to patient survival. Indeed, in the pivotal phase III study in patients with sepsis, the majority of patients had a pulmonary origin, and moreover, patients with pneumonia benefited mostly from rhAPC treatment.27,29,30 

All of the described effects shift the hemostatic balance toward a procoagulant side, promoting fibrin depositions in the airways. The question remains whether this reflects an adaptive mechanism with host protective functions or whether it is a harmful process, predisposing the lungs to secondary complications or perhaps with long-term effects on pulmonary function. Fibrin deposition may be an important mechanism to repair endothelial or epithelial damage; however, an exaggerated coagulation activation has been related to a number of detrimental sequelae. Coagulation products have important proinflammatory effects,31and in addition, ongoing fibrin depositions inactivate surfactant proteins, causing alveolar instability and collapse. Importantly, various anticoagulant strategies have been shown to limit lung injury in experimental studies,32but potential beneficial effects must be confirmed in human patients.

To date, there have been few other reports on the effects of mechanical ventilation in patients with noninjured lungs. Gajic et al.  33,34identified mechanical ventilation with higher tidal volumes as a risk factor for the development of acute lung injury in patients who did not have lung disease at the onset of mechanical ventilation. However, these patients were critically ill patients in an intensive care unit, developing ARDS after 48 h or more. Wrigge et al.  12recently showed that in patients undergoing major surgery with up to 3 h of mechanical ventilation, the ventilation strategy did not affect pulmonary or systemic cytokine levels, suggesting that a brief period of mechanical ventilation does not affect patients without systemic inflammation. Most recently, Wrigge et al.  13extended the duration of mechanical ventilation to 6 h by selecting patients undergoing cardiac surgery. Again, no systemic effects were observed, but postoperative levels of tumor necrosis factor α in bronchoalveolar lavage fluid were lower in patients ventilated with lower tidal volumes. However, measured cytokine levels were very low and highly variable. Therefore, we decided to lavage patients twice, immediately after initiation of mechanical ventilation and 5 h thereafter; this way, every patient would be his or her own control.

We here demonstrate for the first time that mechanical ventilation in patients with normal lungs induces a procoagulant shift in the alveolar hemostatic balance. Mechanical ventilation with lower tidal volumes and PEEP largely attenuates these changes in procoagulant activity within the airways. Clinical studies are warranted to establish the effects of prolonged mechanical ventilation (i.e. , in an intensive care unit) on bronchoalveolar hemostasis, and the relation between alveolar procoagulant activity and patient outcome.

1.
Levi M, Schultz MJ, Rijneveld AW, van der Poll T: Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31:S238–42
2.
Abraham E: Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22:401–4
3.
Günther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia: Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161:454–62
4.
Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, Van Der Zee JS, Speelman P, Carmeliet P, van der Poll T: Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102:934–9
5.
Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T: Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator-associated pneumonia. Thorax 2004; 59:130–5
6.
Choi G, Schultz MJ, van Till JW, Bresser P, Van Der Zee JS, Boermeester MA, Levi M, van der Poll T: Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24:786–9
7.
Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ: Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261:L240–8
8.
Slutsky AS: Lung injury caused by mechanical ventilation. Chest 1999; 116:9S–15S
9.
Pinhu L, Whitehead T, Evans T, Griffiths M: Ventilator-associated lung injury. Lancet 2003; 361:332–40
10.
The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301–8
The Acute Respiratory Distress Syndrome Network
11.
Ranieri VM, Suter PM, Tortorella C, De Tullio, R, Dayer JM, Brienza A, Bruno F, Slutsky AS: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial. JAMA 1999; 282:54–61
12.
Wrigge H, Uhlig U, Zinserling J, Behrends-Callsen E, Ottersbach G, Fischer M, Uhlig S, Putensen C: The effects of different ventilatory settings on pulmonary and systemic inflammatory responses during major surgery. Anesth Analg 2004; 98:775–81
13.
Wrigge H, Uhlig U, Baumgarten G, Menzenbach J, Zinserling J, Ernst M, Dromann D, Welz A, Uhlig S, Putensen C: Mechanical ventilation strategies and inflammatory responses to cardiac surgery: A prospective randomized clinical trial. Intensive Care Med 2005; 31:1379–87
14.
Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, Van Der Zee JS, Bresser P, van der PT: Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005; 172:878–84
15.
van der Poll T, Levi M, Nick JA, Abraham E: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171:1125–8
16.
Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR: Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103:2555–9
17.
Liaw PC, Ferrell G, Esmon CT: A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost 2003; 1:662–70
18.
Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA: Transfusion-related acute lung injury: Report of a clinical look-back investigation. JAMA 2002; 287:1968–71
19.
Ranieri VM, Giunta F, Suter PM, Slutsky AS: Mechanical ventilation as a mediator of multisystem organ failure in acute respiratory distress syndrome. JAMA 2000; 284:43–4
20.
Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, Hafner D, Taut FJ, Seeger W: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884–92
21.
Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867–903
22.
Maris NA, de Vos AF, Bresser P, Van Der Zee JS, Meijers JC, Lijnen HR, Levi M, Jansen HM, van der Poll T: Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers. Thromb Haemost 2005; 93:1036–40
23.
Muth H, Maus U, Wygrecka M, Lohmeyer J, Grimminger F, Seeger W, Günther A: Pro- and antifibrinolytic properties of human pulmonary microvascular versus  artery endothelial cells: Impact of endotoxin and tumor necrosis factor-alpha. Crit Care Med 2004; 32:217–26
24.
Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, Grimminger F, Seeger W, Günther A: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus  intravenous endotoxin application. Thromb Haemost 2004; 92:529–40
25.
Idell S: Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003; 31:S213–20
26.
Choi G, Schultz MJ, Levi M, van der Poll T, Millo JL, Garrard CS: Protein C in pneumonia. Thorax 2005; 60:705–6
27.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699–709
28.
Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via  inhibition of neutrophil chemotaxis. Blood 2004; 104:3878–85
29.
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G III, Bernard GR: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31:834–40
30.
Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SC, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 2005; 33:952–61
31.
Levi M, van der Poll T, Büller HR: Bidirectional relation between inflammation and coagulation. Circulation 2004; 109:2698–704
32.
Laterre PF, Wittebole X, Dhainaut JF: Anticoagulant therapy in acute lung injury. Crit Care Med 2003; 31:S329–36
33.
Gajic O, Dara SI, Mendez JL, Adesanya AO, Festic E, Caples SM, Rana R, St Sauver JL, Lymp JF, Afessa B, Hubmayr RD: Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 2004; 32:1817–24
34.
Gajic O, Frutos-Vivar F, Esteban A, Hubmayr RD, Anzueto A: Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med 2005; 31:922–6